Dr Reddy’s Labs terminates Kuwait-based Covid-19 treatment study

Dr Reddy’s Labs terminates Kuwait-based Covid-19 treatment study
Share This :

Dr Reddy’s Laboratories on Wednesday announced termination of Avigan trial study being conducted in Kuwait that was focused on moderate to severe COVID-19 patients in a hospital setting.

It was one of the studies in the overall clinical programme for Fujifilm’s Avigan, an antiviral medication, spanning the spectrum of asymptomatic to severe cases of COVID-19 in both outpatient and inpatient setting, the drug major said in a statement.

The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by the company in partnership with Appili Therapuetics and Global Response Aid, shall continue, it added.

The data from the Kuwait study involving moderate-severe COVID-19 hospitalised patients did not show statistically significant difference for the primary endpoint, the Hyderabad-based drugmaker said.

The full data analysis on 353 subjects would be available by the end of February 2021, it added.

Elaborating on the study, Dr Reddy’s said sub-group analysis was carried out on 181 subjects in the low risk category.

The sub-group analysis of the low-risk category demonstrated a three-day earlier discharge in the Avigan group compared to the placebo group for time to hospital discharge secondary endpoint, it added.

“The sub-group analysis data during the initial interim analysis points towards the hypothesis with clinically significant insights from this study that an antiviral drug like Avigan may be effective as part of early treatment initiation in COVID-19 patients and not effective in the late-stage hospital treatment for moderate and severe COVID-19 patients,” the drugmaker said.

, Dr Reddy’s Labs terminates Kuwait-based Covid-19 treatment study, Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Source link

Share This :